Open an account

Aurinia Pharmaceuticals

AUPH · NASDAQ

$16.74+$0.25 (+1.52%)TodayMarket closed ·
Prev close $16.49

About AUPH

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The firm is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The firm is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. The company sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The firm sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.

Employees
300
Headquarters
Edmonton, British Columbia
Listed
Jul 16, 2001
Sector
Health Care
Industry
Biotechnology
Website
auriniapharma.com

AUPH key statistics

Market cap
2.23B
Price-earnings ratio
7.23
Dividend yield
—
Average volume
824.56K
Volume
593.68K
Open price
$16.60
High today
$16.83
Low today
$16.56
52 Week high
$19.25
52 Week low
$11.39

Aurinia Pharmaceuticals (AUPH) at a glance

As of Oct 20, 2026, Aurinia Pharmaceuticals (AUPH) shares are priced at $16.74, giving the company a market cap of 2.23B and a price-to-earnings ratio of 7.23.

Today the stock has traded between $16.56 and $16.83. The current price is 1.1% above the day's low and 0.5% below its high.

Volume so far is 593.68K shares, below the average of 824.56K shares a day.

Over the past year Aurinia Pharmaceuticals has ranged from $11.39 to $19.25, and now sits 68% of the way up that range.

Aurinia Pharmaceuticals met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $0.28 per share against an estimate of $0.2448.

The average analyst price target is $18.21, 8.8% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

33%of 3 analyst ratings say Buy
  • Buy33.3%
  • Hold66.7%
  • Sell0.0%
Price target · 9 analystsAvg $18.21
Low
$16.16
Now
$16.74
High
$22.05

AUPH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 109.4% on average.

  1. Q3 FY24: reported $0.10 per share against an estimate of $0.0153
  2. Q4 FY24: reported $0.01 per share against an estimate of -$0.0163
  3. Q1 FY25: reported $0.16 per share against an estimate of $0.102
  4. Q2 FY25: reported $0.16 per share against an estimate of $0.1496
  5. Q3 FY25: reported $0.23 per share against an estimate of $0.1632
  6. Q4 FY25: reported $0.26 per share against an estimate of $0.221
  7. Q1 FY26: reported $0.25 per share against an estimate of $0.202
  8. Q2 FY26: reported $0.28 per share against an estimate of $0.2448

AUPH news

  • Vandana Singh

    Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

  • Press releaseBusiness Wire

    Aurinia Settles Patent Litigation with Teva

  • Press releaseBusiness Wire

    Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

  • Press releaseBusiness Wire

    Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

  • Press releaseBusiness Wire

    LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

  • Tang Capital Raises Aurinia Pharmaceuticals Holding to 10%

  • Press releasePRNewswire

    TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.

  • Press releaseBusiness Wire

    Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

Similar companies

Companies in the same industry as Aurinia Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.